Skip to content

Influence of Food Preferences on the Occurrence of Undernutrition in Treated Patients for Bronchopulmonary Carcinoma Non-small Cell Stage IV

Influence of Food Preferences on the Occurrence of Undernutrition in Treated Patients for Bronchopulmonary Carcinoma Non-small Cell Stage IV

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05496556
Acronym
ONCOGOU
Enrollment
190
Registered
2022-08-11
Start date
2023-11-01
Completion date
2026-10-01
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Bronchopulmonary Carcinoma at Stage IV and Benefiting From First-line Treatment According to Current French Recommendations

Brief summary

The study will be offered to patients with non-small cell lung carcinoma diagnosed at stage IV and receiving first-line treatment. The patient will benefit from a complete assessment at inclusion (clinical exam, imagery, biological exam, dietary consultation, test LFQP. At the end of this 1st evaluation, patients in whom the diagnosis of undernutrition is made will benefit from dietary management with personalized advice that will take into account the symptoms of cancer, the possible side effects of treatments as well as the social environment. Every two cures, i.e. every 4 to 6 weeks, these examens will be performed until the occurrence of an event (progression of the disease according to the RECIST criteria, death or change of therapeutic line). At the end of these assessments, patients will benefit from dietary management with a readjustment of personalized advice that will take into account the difficulties highlighted during the assessment.

Interventions

OTHERTest Leeds Food Preference Questionnaire (LFQP-France)

The version of this questionnaire has been adapted to French eating habits. and based on the presentation of food photos, each representing one of the four categories below : salty-high in fat / salty-low fat / sugary-high fat / sweet-low fat The answers given to the LFQP predict a more or less caloric food intake. This tool makes it possible to objectify changes in eating behavior according to the nutritional status and protein status of patients. The implied wanting score for salty-high-fat, salty-low-fat, sweet-high-fat, and sweet-low-fat foods is calculated based on the frequency and speed of choice for one food type out of 150 combinations. For each of the food modalities, the software will return a score with its standard deviation. The modality preferred by the patient is the one with the highest score

Sponsors

Centre Georges Francois Leclerc
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of stage IV non-small cell lung carcinoma with indication for first-line systemic treatment (chemotherapy, immunotherapy or specific treatment, in particular tyrosine kinase inhibitors) according to current French recommendations. * Age over 18 and under 70 * Patient speaking and reading French fluently * Affiliation to a social security scheme * Patient able and willing to follow all study procedures in accordance with the protocol * Patient having understood, signed and dated the consent form

Exclusion criteria

* Patient requiring hospitalization for more than 48 hours for the administration of the first course of treatment * Patient benefiting from antibiotic therapy for the treatment of an acute infection * Psychiatric, cognitive or neurological disorders making it impossible to assess food preferences and/or any impossibility to undergo medical monitoring for the trial for geographical, social or psychological reasons. * Daily alcohol consumption * Chest radiotherapy treatment * Pregnant woman, likely to be, or breastfeeding * Persons deprived of liberty or under guardianship

Design outcomes

Primary

MeasureTime frameDescription
Measurement of implicit wanting by the LFQP-France questionnaireDuring patient follow-up (12 months max)The food category with the highest implicit wanting score will be retained as characterizing the patient's food preferences. The 4 categories concerned are as follows: * salty high in fat * salty-low fat * sweet-high fat * sweet-low fat

Secondary

MeasureTime frameDescription
The occurrence of undernutrition within 6 months after inclusion, in patients not undernourished at inclusionDuring 6 monthsThe food category with the highest implicit wanting score will be retained as characterizing the patient's food preferences. The 4 categories concerned are as follows: * salty high in fat * salty-low fat * sweet-high fat * sweet-low fat
The impact of food preferences (liking and explicit wanting) assessed by the LFQP-France questionnaire on the prevalence and incidence of undernutrition in the 6 months after inclusion.During 6 monthsThe food category with the highest implicit wanting score will be retained as characterizing the patient's food preferences. The 4 categories concerned are as follows: * salty high in fat * salty-low fat * sweet-high fat * sweet-low fat
The impact of food preferences (liking, explicit lwanting and implicit wanting) assessed by the LFQP-France questionnaire on the severity of undernutritionthrough study completion, an average of 1 yearThe severity of malnutrition will be determined by serum albumin.
the impact of food preferences (liking, explicit wanting and implicit wanting) assessed by the LFQP-France questionnaire on quality of lifethrough study completion, an average of 1 yearWith the EORTC QLQ-C30 and QLQ-CL13 tests at inclusion, then at each follow-up visit and until exit from the study (premature exit or end of study
The impact of the type of 1st line treatment on food preferences (chemotherapy based on platinum salt versus immunotherapy versus targeted therapy)through study completion, an average of 1 year1st line treatments considered categorized into 3 classes: platinum-based chemotherapy versus immunotherapy versus targeted therapy

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026